Home - Biotech Today

Weekly Market Review – June 25, 2022

Markets June 25, 2022 By News Staff
Civica signs up Profil to run trials for affordable insulin biosimilars

Biotechnology Today June 24, 2022 By News Team
After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor

Biotechnology Today June 24, 2022 By News Team

Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy

Biotechnology Today June 24, 2022 By News Team

Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise

Biotechnology Today June 24, 2022 By News Team

Qiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom

Bio Space June 24, 2022 By News Team

In The News

Economic Storm Clouds Hovering Over Trump and Global Leaders August 25, 2019 By News Team
UN: Possible to Eradicate Malaria, but Probably Not Soon August 24, 2019 By News Team
Climate Change Turns Arctic Into Strategic, Economic Hotspot August 23, 2019 By News Team

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. biotech-today.com is a wholly-owned subsidiary of Maynard Communication Limited.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Weekly Market Review – June 25, 2022

Civica signs up Profil to run trials for affordable insulin biosimilars

After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor

Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy

Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise

Qiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom

In The News

Biotechnology Today

Civica signs up Profil to run trials for affordable insulin biosimilars

After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor

Baxter warns of possible oxygen level drops linked to Hillrom lung-expansion therapy

Good news or bad news? FDA delays decision for Amylyx’s ALS drug—and shares rise

After phase 3 fail, Biogen posts 12-month data cut to make case for ALS prospect

Markets

Weekly Market Review – June 25, 2022

Weekly Market Review – June 18, 2022

Weekly Market Review – June 11, 2022

Weekly Market Review – June 4, 2022

Weekly Market Review – May 28, 2022

Bio Space

Qiming Venture Partners boasts $260M oversubscribed fund, taps biotech leader to impart further wisdom

Why the war in Ukraine might make root canals more difficult

ADA: Abbott plans new wearable sensor for catching diabetic ketoacidosis

Global News

SpaceX Starlink wins permit to send internet to customers like you

Facebook video calls soar 1000% during Italy’s lockdown

WeWork board’s special committee is demanding that SoftBank follow through with investment